Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Downloads
Exports from our negotiations database are available for download in CSV or JSON formats.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Under consideration for negotiation
Manufacturer:
Amgen Canada Inc.
Indication:
Thyroid Eye Disease
Last updated:
May 5, 2026
Status:
Active negotiation
Manufacturer:
Sanofi Genzyme Canada
Indication:
Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
Last updated:
April 30, 2026
Blenrep (belantamab mafodotin) (in combination with bortezomib and dexamethasone)
Status:
Active negotiation
Manufacturer:
GlaxoSmithKline Inc.
Indication:
For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Last updated:
April 30, 2026
Blenrep (belantamab mafodotin) (in combination with pomalidomide and dexamethasone)
Status:
Active negotiation
Manufacturer:
GlaxoSmithKline Inc.
Indication:
For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide.
Last updated:
April 30, 2026
Status:
Active negotiation
Manufacturer:
Xediton Pharmaceuticals Inc.
Indication:
in combination with doxorubicin as first-line treatment for advanced unresectable
Last updated:
April 29, 2026